DOW JONES21,052.53-360.91 -1.69%
S&P 5002,488.65-38.25 -1.51%
NASDAQ7,373.08-114.23 -1.53%

Bellicum Pharmaceuticals Q4 EPS $(5.82) May Not Compare To $(4) Estimate, Sales $133K Miss $630K Estimate

Bellicum Pharmaceuticals (NASDAQ:BLCM) reported quarterly losses of $(5.82) per share which missed the analyst consensus estimate of $(4) by 45.5 percent. This is a 7.18 percent increase over losses of $(6.27) per share

Benzinga · 03/12/2020 20:18

Bellicum Pharmaceuticals (NASDAQ:BLCM) reported quarterly losses of $(5.82) per share which missed the analyst consensus estimate of $(4) by 45.5 percent. This is a 7.18 percent increase over losses of $(6.27) per share from the same period last year. The company reported quarterly sales of $133 thousand which missed the analyst consensus estimate of $630 thousand by 78.89 percent. This is a 57.37 percent decrease over sales of $312 thousand the same period last year.